{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:59:48Z","timestamp":1769007588754,"version":"3.49.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","internationaljournalofcardiology.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ijcard.2016.10.102","type":"journal-article","created":{"date-parts":[[2016,11,2]],"date-time":"2016-11-02T15:30:18Z","timestamp":1478100618000},"page":"556-564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6079-7360","authenticated-orcid":false,"given":"Kinjal","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raktim Kumar","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sravani","family":"Kamatam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnab","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2016.10.102_bb0005","first-page":"e38","article-title":"Heart disease and stroke statistics\u20142016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0010","author":"National Center for Biotechnology Information"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0015","author":"FDA"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0020","author":"Gilead Sciences"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical pharmacokinetics of ranolazine","volume":"45","author":"Jerling","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0030","doi-asserted-by":"crossref","first-page":"e003196","DOI":"10.1161\/JAHA.116.003196","article-title":"Ranolazine: A Contemporary Review","volume":"5","author":"Rayner-Hartley","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0035","series-title":"Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine","author":"Zipes","year":"2015"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0040","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.yjmcc.2008.03.019","article-title":"Late sodium current inhibition as a new cardioprotective approach","volume":"44","author":"Hale","year":"2008","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0045","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/j.hrthm.2011.03.045","article-title":"Electrophysiologic basis for the antiarrhythmic actions of ranolazine","volume":"8","author":"Antzelevitch","year":"2011","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0050","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.2337\/db13-1562","article-title":"Blockade of Na+channels in pancreatic \u03b1-cells has antidiabetic effects","volume":"63","author":"Dhalla","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/jpet.110.176396","article-title":"Ranolazine increases \u03b2-cell survival and improves glucose homeostasis in low-dose Streptozotocin-induced diabetes in mice","volume":"337","author":"Ning","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0060","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1113\/jphysiol.2013.257246","article-title":"Ranolazine recruits muscle microvasculature and enhances insulin action in rats","volume":"591","author":"Fu","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0065","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijcard.2015.03.324","article-title":"Antiarrhythmic properties of ranolazine: a review of the current evidence","volume":"187","author":"Gupta","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0070","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1161\/CIRCULATIONAHA.105.597500","article-title":"Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions","volume":"113","author":"Chaitman","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0075","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s002100000378","article-title":"Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system","volume":"363","author":"L\u00e9tienne","year":"2001","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0080","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1592\/phco.2006.26.1.135","article-title":"Ranolazine, a novel agent for chronic stable angina","volume":"26","author":"Gaffney","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"Suppl. 4","key":"10.1016\/j.ijcard.2016.10.102_bb0085","first-page":"iv6","article-title":"Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine","volume":"92","author":"Belardinelli","year":"2006","journal-title":"Heart"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0090","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0095","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0100","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","article-title":"Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial","volume":"48","author":"Stone","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0105","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.amjcard.2013.11.070","article-title":"The usefulness of ranolazine for the treatment of refractory chronic stable angina pectoris as determined from a systematic review of randomized controlled trials","volume":"113","author":"Banon","year":"2014","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0110","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ijcard.2013.08.131","article-title":"Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis","volume":"169","author":"Savarese","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijcard.2016.02.140","article-title":"A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris","volume":"211","author":"Vellopoulou","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0120","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1161\/CIRCULATIONAHA.107.763912","article-title":"Evaluation of the glycometabolic effects of ranolazine in patients with and without diabetes mellitus in the MERLIN-TIMI 36 randomized controlled trial","volume":"119","author":"Morrow","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0125","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1161\/CIRCULATIONAHA.107.724880","volume":"116","author":"Scirica","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0130","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.hrthm.2015.01.021","article-title":"Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (ranolazine in atrial fibrillation following an electrical cardioversion) study","volume":"12","author":"De Ferrari","year":"2015","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0135","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2012.04.044","article-title":"Comparison of effectiveness of ranolazine plus amiodarone versus amiodarone alone for conversion of recent-onset atrial fibrillation","volume":"110","author":"Fragakis","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0140","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/europace\/eut407","article-title":"Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation","volume":"16","author":"Koskinas","year":"2014","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0145","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1161\/CIRCEP.115.002856","article-title":"The HARMONY trial: combined ranolazine and dronedarone in the management of paroxysmal atrial fibrillation: mechanistic and therapeutic synergism","volume":"8","author":"Reiffel","year":"2015","journal-title":"Circ. Arrhythmia Electrophysiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0150","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.yjmcc.2016.03.012","article-title":"The combined effects of ranolazine and dronedarone on human atrial and ventricular electrophysiology","volume":"94","author":"Hartmann","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0155","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1177\/0003319713477911","article-title":"Ranolazine enhances the antiarrhythmic activity of amiodarone by accelerating conversion of new-onset atrial fibrillation after cardiac surgery","volume":"65","author":"Simopoulos","year":"2014","journal-title":"Angiology"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2011.04.017","article-title":"Comparison of effectiveness and safety of ranolazine versus amiodarone for preventing atrial fibrillation after coronary artery bypass grafting","volume":"108","author":"Miles","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0165","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2217\/fca.11.67","article-title":"Ranolazine versus amiodarone for prevention of postoperative atrial fibrillation","volume":"7","author":"Burashnikov","year":"2011","journal-title":"Futur. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0170","doi-asserted-by":"crossref","first-page":"988","DOI":"10.2174\/157016111106140128123506","article-title":"Effect of ranolazine in preventing postoperative atrial fibrillation in patients undergoing coronary revascularization surgery","volume":"11","author":"Tagarakis","year":"2013","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0175","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s00392-014-0796-x","article-title":"Short-course of ranolazine prevents postoperative atrial fibrillation following coronary artery bypass grafting and valve surgeries","volume":"104","author":"Hammond","year":"2015","journal-title":"Clin. Res. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0185","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ahj.2013.08.004","article-title":"Use of ranolazine in patients with incomplete revascularization after percutaneous coronary intervention: design and rationale of the ranolazine for incomplete vessel revascularization post-percutaneous coronary intervention (RIVER-PCI) trial","volume":"166","author":"Weisz","year":"2013","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0190","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0140-6736(15)00459-6","article-title":"Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"387","author":"Weisz","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0195","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/eurheartj\/ehm567","article-title":"Right coronary artery flow impairment in patients with pulmonary hypertension","volume":"29","author":"van Wolferen","year":"2008","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0200","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.amjmed.2004.01.002","article-title":"Evaluation and treatment for angina in pulmonary arterial hypertension","volume":"116","author":"Barst","year":"2004","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5115\/acb.2016.49.1.7","article-title":"Reduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatment","volume":"49","author":"Lee","year":"2016","journal-title":"Anat. Cell Biol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0210","article-title":"Ranolazine reduces remodeling of the right ventricle and provoked arrhythmias in rats with pulmonary hypertension","volume":"480\u2013489","author":"Liles","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0215","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/cvr\/cvu188","article-title":"Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension","volume":"104","author":"Rocchetti","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0220","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1086\/682427","article-title":"Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study","volume":"5","author":"Khan","year":"2015","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0225","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1086\/683813","article-title":"Phase I safety study of ranolazine in pulmonary arterial hypertension","volume":"5","author":"Gomberg-Maitland","year":"2015","journal-title":"Pulm. Circ."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0230","author":"Waxman"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0235","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00877121","article-title":"Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease","volume":"8","author":"Hayashida","year":"1994","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0240","author":"Maier"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0245","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/clc.20897","article-title":"Ranolazine for the treatment of heart failure with preserved ejection fraction: background, aims, and design of the RALI-DHF study","volume":"34","author":"Jacobshagen","year":"2011","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0250","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jchf.2012.12.002","article-title":"RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction. The RALI-DHF proof-of-concept study","volume":"1","author":"Maier","year":"2013","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0255","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1177\/1074248410382105","article-title":"Improvement in left ventricular systolic and diastolic performance during ranolazine treatment in patients with stable angina","volume":"16","author":"Figueredo","year":"2011","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0260","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13104-016-1874-0","article-title":"Effect of late sodium current inhibition on MRI measured diastolic dysfunction in aortic stenosis: a pilot study","volume":"9","author":"Singh","year":"2016","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0265","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11886-015-0570-3","article-title":"Advanced heart failure due to cancer therapy","volume":"17","author":"Shah","year":"2015","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0270","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/ejhf.50","article-title":"Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction","volume":"16","author":"Tocchetti","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0275","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.phrs.2013.11.001","article-title":"Ranolazine in the prevention of anthracycline cardiotoxicity","volume":"79","author":"Corradi","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0280","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/jpet.113.204057","article-title":"Pharmacology at work for cardio-oncology: ranolazine to treat early cardiotoxicity induced by antitumor drugs","volume":"346","author":"Minotti","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0285","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1093\/eurheartj\/ehi495","article-title":"Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes","volume":"27","author":"Timmis","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0290","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2337\/dc09-2334","article-title":"Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome","volume":"33","author":"Chisholm","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0295","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2337\/dc14-2629","article-title":"Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes","volume":"38","author":"Eckel","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0300","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/dom.12629","article-title":"Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin","volume":"18","author":"Pettus","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0305","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina)","volume":"61","author":"Kosiborod","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0310","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jacc.2013.07.122","article-title":"Reply: in regard to the TERISA trial","volume":"64","author":"Kosiborod","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0315","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijcard.2016.06.003","article-title":"Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study","volume":"219","author":"Caminiti","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0320","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1161\/CIRCOUTCOMES.113.000752","article-title":"Comparison of the Seattle angina questionnaire with daily angina diary in the TERISA clinical trial","volume":"7","author":"Arnold","year":"2014","journal-title":"Circ. Qual. Outcomes"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0325","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ahj.2014.06.020","article-title":"Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c","volume":"168","author":"Arnold","year":"2014","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0330","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.ahj.2015.07.025","article-title":"Glucose-lowering medications and angina burden in patients with stable coronary disease: results from the type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina (TERISA) trial","volume":"170","author":"Arnold","year":"2015","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0340","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1177\/2047487312450133","volume":"19","author":"Send\u00f3n","year":"2012","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0345","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0350","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jacc.2009.09.068","article-title":"B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary-Thr)","volume":"55","author":"Morrow","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0355","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1161\/CIRCULATIONAHA.109.897231","article-title":"Clinical features and outcomes of women with unstable ischemic heart disease: observations from metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndromes-thrombolysis in myocardial infarction 36 (MERLIN-TIMI 36)","volume":"121","author":"Mega","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0360","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/europace\/euu217","article-title":"Effect of ranolazine on atrial fibrillation in patients with non-ST elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial","volume":"17","author":"Scirica","year":"2015","journal-title":"Europace"},{"key":"10.1016\/j.ijcard.2016.10.102_bb0365","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/clc.22425","article-title":"Effects of ranolazine in patients with chronic angina in patients with and without percutaneous coronary intervention for acute coronary syndrome: observations from the MERLIN-TIMI 36 trial","volume":"38","author":"Gutierrez","year":"2015","journal-title":"Clin. Cardiol."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0370","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.hrthm.2015.01.021","article-title":"Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging RAFFAELLO (Ranolazine in Atrial Fibrillation Following an ELectricaL CardiOversion) study","volume":"12","author":"De Ferrari","year":"2015","journal-title":"Heart Rhythm."},{"key":"10.1016\/j.ijcard.2016.10.102_bb0375","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1086\/683813","article-title":"Phase I safety study of ranolazine in pulmonary arterial hypertension","volume":"5","author":"Gomberg-Maitland","year":"2015","journal-title":"Pulm. Circ."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316333204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527316333204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T09:26:50Z","timestamp":1556357210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527316333204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":73,"alternative-id":["S0167527316333204"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.102","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Ranolazine in cardiovascular disease and diabetes: Exploring beyond angina","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2016.10.102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}